The authors of the study showed that PCYT1A was overexpressed in 44% of the analyzed DLBCL patients and that PCYT1A overexpression occurred in parallel with the enhanced gene and protein expression of MYC [119], an oncogene mostly involved in lymphoma cell chemoresistance [165]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.